Clio P. Mavragani
Cited by
Cited by
Sjögrenís syndrome
CP Mavragani, GE Fragoulis, HM Moutsopoulos
The Autoimmune Diseases, 495-510, 2014
The geoepidemiology of Sjögren's syndrome
CP Mavragani, HM Moutsopoulos
Autoimmunity reviews 9 (5), A305-A310, 2010
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
M Dastmalchi, C Grundtman, H Alexanderson, CP Mavragani, ...
Annals of the rheumatic diseases 67 (12), 1670-1677, 2008
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis
A Nezos, F Gravani, A Tassidou, EK Kapsogeorgou, M Voulgarelis, ...
Journal of autoimmunity 63, 47-58, 2015
Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use
S Fragkioudaki, CP Mavragani, HM Moutsopoulos
Medicine 95 (25), 2016
Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanercept
CP Mavragani, TB Niewold, NM Moutsopoulos, SR Pillemer, SM Wahl, ...
Arthritis & Rheumatism: Official Journal of the American College of†Ö, 2007
Activation of the type I interferon pathway in primary Sjogrenís syndrome
CP Mavragani, MK Crow
Journal of autoimmunity 35 (3), 225-231, 2010
The management of Sjögren's syndrome
CP Mavragani, NM Moutsopoulos, HM Moutsopoulos
Nature clinical practice Rheumatology 2 (5), 252-261, 2006
Cardiovascular disease in systemic lupus erythematosus: a comprehensive update
M Giannelou, CP Mavragani
Journal of autoimmunity 82, 1-12, 2017
Central nervous system involvement in Sjögrenís syndrome
FC Soliotis, CP Mavragani, HM Moutsopoulos
Annals of the rheumatic diseases 63 (6), 616-620, 2004
Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease
CP Mavragani, I Sagalovskiy, Q Guo, A Nezos, EK Kapsogeorgou, P Lu, ...
Arthritis & rheumatology 68 (11), 2686-2696, 2016
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
A Nezos, A Papageorgiou, G Fragoulis, D Ioakeimidis, M Koutsilieris, ...
Journal of autoimmunity 51, 89-98, 2014
Predicting the outcome of Sjogrenís syndrome-associated non-hodgkinís lymphoma patients
A Papageorgiou, DC Ziogas, CP Mavragani, E Zintzaras, AG Tzioufas, ...
PloS one 10 (2), e0116189, 2015
Conventional therapy of Sjogrenís syndrome
CP Mavragani, HM Moutsopoulos
Clinical reviews in allergy & immunology 32, 284-291, 2007
Sjögren's syndrome: old and new therapeutic targets
CP Mavragani, HM Moutsopoulos
Journal of autoimmunity 110, 102364, 2020
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon‐β/α ratios in rheumatoid arthritis patients: a post hoc†Ö
CP Mavragani, DT La, W Stohl, MK Crow
Arthritis & Rheumatism: Official Journal of the American College of†Ö, 2010
Endocrine alterations in primary Sjogren's syndrome: an overview
CP Mavragani, GE Fragoulis, HM Moutsopoulos
Journal of autoimmunity 39 (4), 354-358, 2012
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogrenís syndrome: prevalence, clinical and laboratory associations
F Gravani, I Papadaki, E Antypa, A Nezos, K Masselou, D Ioakeimidis, ...
Arthritis research & therapy 17 (1), 1-13, 2015
Fatigue in primary Sjögren's syndrome: clinical, laboratory, psychometric, and biologic associations
T Karageorgas, S Fragioudaki, A Nezos, D Karaiskos, HM Moutsopoulos, ...
Arthritis care & research 68 (1), 123-131, 2016
Adult-onset Stillís disease: from pathophysiology to targeted therapies
CP Mavragani, EG Spyridakis, M Koutsilieris
International journal of inflammation 2012, 2012
The system can't perform the operation now. Try again later.
Articles 1–20